Pasithea Therapeutics Corp.

NASDAQ: KTTA

Company Logo

Company Overview

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Its biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders rather than symptomatic treatments, with the goal of developing new pharmacological agents that display significant advantages over conventional therapies with respect to efficacy and tolerability.

The Company’s secondary operations focus on providing business support services to anti-depression clinics in the United Kingdom and in the United States. The Company’s operations in the United Kingdom will involve providing business support services to registered healthcare providers who will assess patients, and if appropriate, administer intravenous infusions of ketamine, and the Company’s operations in the United States will involve providing business support services to entities that furnish similar services to patients who personally pay for those services. Pasithea has partnered with two successful clinics for immediate exposure in locations across Los Angeles, New York City and London.

Financial Highlights

$0

Revenue (ttm)

$0

Gross Profit (ttm)

-$0.35

Diluted EPS (ttm)

Management Team

Dr. Tiago Reis Marques
CEO & Director

Prof. Lawrence Steinman BA, M.D.
Exec. Chairman & Co-Founder

Mr. Stanley M. Gloss
Chief Financial Officer

Dr. Yassine Bendiabdallah
COO, Head of UK Clinics & Director

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
()

Insider Ownership
58%